290 related articles for article (PubMed ID: 29727322)
1. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
Nguyen JK; Magi-Galluzzi C
Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
[TBL] [Abstract][Full Text] [Related]
2. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
3. Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.
Rubin MA; Girelli G; Demichelis F
Eur Urol; 2016 Apr; 69(4):557-560. PubMed ID: 26563871
[TBL] [Abstract][Full Text] [Related]
4. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
[TBL] [Abstract][Full Text] [Related]
5. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
Punnen S; Parekh DJ
J Urol; 2017 Aug; 198(2):266-267. PubMed ID: 28629663
[No Abstract] [Full Text] [Related]
6. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
Palapattu GS
J Urol; 2017 Aug; 198(2):265-266. PubMed ID: 28629664
[No Abstract] [Full Text] [Related]
7. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
8. Genomic tests to guide prostate cancer management following diagnosis.
Colicchia M; Morlacco A; Cheville JC; Karnes RJ
Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
[TBL] [Abstract][Full Text] [Related]
9. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
Taylor AS; Morgan TM; Wallington DG; Chinnaiyan AM; Spratt DE; Mehra R
Prostate; 2020 Feb; 80(2):146-152. PubMed ID: 31737920
[TBL] [Abstract][Full Text] [Related]
11. Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.
Schachtschneider KM; Gaba RC
J Vasc Interv Radiol; 2018 Aug; 29(8):1117-1121. PubMed ID: 30055782
[No Abstract] [Full Text] [Related]
12. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
13. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
14. Contemporary grading for prostate cancer: implications for patient care.
Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
[TBL] [Abstract][Full Text] [Related]
15. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
[TBL] [Abstract][Full Text] [Related]
16. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
[TBL] [Abstract][Full Text] [Related]
17. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
[TBL] [Abstract][Full Text] [Related]
18. Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.
Alexander J; Kendall J; McIndoo J; Rodgers L; Aboukhalil R; Levy D; Stepansky A; Sun G; Chobardjiev L; Riggs M; Cox H; Hakker I; Nowak DG; Laze J; Llukani E; Srivastava A; Gruschow S; Yadav SS; Robinson B; Atwal G; Trotman LC; Lepor H; Hicks J; Wigler M; Krasnitz A
Cancer Res; 2018 Jan; 78(2):348-358. PubMed ID: 29180472
[TBL] [Abstract][Full Text] [Related]
19. Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier.
Herlemann A; Washington SL; Eapen RS; Cooperberg MR
Urol Clin North Am; 2017 Nov; 44(4):547-555. PubMed ID: 29107271
[TBL] [Abstract][Full Text] [Related]
20. Leveraging Genomic Factors to Improve Benefit-Risk.
Schuck RN; Charlab R; Blumenthal GM
Clin Transl Sci; 2017 Mar; 10(2):78-83. PubMed ID: 28160443
[No Abstract] [Full Text] [Related]
[Next] [New Search]
